ATE391774T1 - Verwendung von bakterien mit arginin- deiminaseaktivität zur induktion der apoptose und/oder zur hemmung einer entzündungsreaktion, und diese enthaltende pharmazeutische oder diätetische zusammensetzungen - Google Patents

Verwendung von bakterien mit arginin- deiminaseaktivität zur induktion der apoptose und/oder zur hemmung einer entzündungsreaktion, und diese enthaltende pharmazeutische oder diätetische zusammensetzungen

Info

Publication number
ATE391774T1
ATE391774T1 AT98950301T AT98950301T ATE391774T1 AT E391774 T1 ATE391774 T1 AT E391774T1 AT 98950301 T AT98950301 T AT 98950301T AT 98950301 T AT98950301 T AT 98950301T AT E391774 T1 ATE391774 T1 AT E391774T1
Authority
AT
Austria
Prior art keywords
inhibiting
bacteria
pharmaceutical
compositions containing
same
Prior art date
Application number
AT98950301T
Other languages
German (de)
English (en)
Inventor
Simone Claudio De
Original Assignee
Actial Farmaceutica Lda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actial Farmaceutica Lda filed Critical Actial Farmaceutica Lda
Application granted granted Critical
Publication of ATE391774T1 publication Critical patent/ATE391774T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/24—Lactobacillus brevis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98950301T 1998-02-20 1998-10-13 Verwendung von bakterien mit arginin- deiminaseaktivität zur induktion der apoptose und/oder zur hemmung einer entzündungsreaktion, und diese enthaltende pharmazeutische oder diätetische zusammensetzungen ATE391774T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT98RM000103A IT1298918B1 (it) 1998-02-20 1998-02-20 Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche

Publications (1)

Publication Number Publication Date
ATE391774T1 true ATE391774T1 (de) 2008-04-15

Family

ID=11405583

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98950301T ATE391774T1 (de) 1998-02-20 1998-10-13 Verwendung von bakterien mit arginin- deiminaseaktivität zur induktion der apoptose und/oder zur hemmung einer entzündungsreaktion, und diese enthaltende pharmazeutische oder diätetische zusammensetzungen

Country Status (24)

Country Link
US (2) US6572854B1 (member.php)
EP (1) EP1058725B1 (member.php)
JP (1) JP4253439B2 (member.php)
KR (1) KR100594569B1 (member.php)
CN (1) CN1189560C (member.php)
AR (2) AR020053A1 (member.php)
AT (1) ATE391774T1 (member.php)
AU (1) AU754483B2 (member.php)
BR (1) BR9815677A (member.php)
CA (1) CA2321263C (member.php)
CY (1) CY1108112T1 (member.php)
DE (1) DE69839351T2 (member.php)
DK (1) DK1058725T3 (member.php)
EA (1) EA006018B1 (member.php)
ES (1) ES2303357T3 (member.php)
IL (1) IL137799A (member.php)
IN (2) IN1999KO00116A (member.php)
IT (1) IT1298918B1 (member.php)
MX (1) MX237377B (member.php)
PT (1) PT1058725E (member.php)
SI (1) SI1058725T1 (member.php)
TR (1) TR200002326T2 (member.php)
WO (1) WO1999042568A1 (member.php)
ZA (1) ZA9811619B (member.php)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1296148B1 (it) * 1996-11-22 1999-06-09 Renata Maria Anna Ve Cavaliere Uso di batteri lattici per accrescere il livello delle ceramidi della pelle e delle mucose, e composizioni dermatologiche e cosmetiche atte
IT1311495B1 (it) * 1999-06-09 2002-03-13 Mendes S U R L Composizione comprendente sfingomielinasi alcalina, utilizzabile qualeprodotto dietetico, integratore alimentare o medicamento.
US8697051B2 (en) * 1999-06-09 2014-04-15 Vsl Pharmaceuticals Inc. Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
IT1306716B1 (it) * 1999-06-21 2001-10-02 Mendes S U R L Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori.
AUPQ415899A0 (en) * 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
HU227086B1 (en) * 1999-11-25 2010-06-28 Vakcina Kft Lactobacillus vaccine for treating prostata inflammatory and benign prostata hyperplasia
FR2809312B1 (fr) * 2000-05-25 2002-07-12 Gervais Danone Sa Utilisation de l. casei dans des compositions immunostimulantes
US6767537B2 (en) * 2000-05-26 2004-07-27 Phil Arnold Nicolay Composition and method for the treatment of sinusitis
MXPA04001999A (es) * 2001-09-05 2004-07-16 Vsl Pharmaceuticals Inc Bacterias de acido lactico que comprende dinucleotidos de citosina-guanina no metilados para usarse en terapia.
ITRM20010763A1 (it) * 2001-12-21 2003-06-21 Simone Claudio De Nuovo ceppo di batterio lattico e composizioni commestibili, farmaci e prodotti veterinari che lo contengono.
CA2506244C (en) * 2002-11-18 2012-10-30 Phoenix Pharmacologics, Inc. Methods for inhibiting viral replication in vivo
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
TW200700074A (en) * 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
EP2270131A1 (en) 2005-05-31 2011-01-05 The Iams Company Feline probiotic lactobacilli
EP1885383B1 (en) 2005-05-31 2016-09-21 IAMS Europe B.V. Feline probiotic bifidobacteria
EA016734B1 (ru) 2006-12-21 2012-07-30 Калпис Ко., Лтд. СРЕДСТВА ДЛЯ СТИМУЛЯЦИИ ПРОДУЦИРОВАНИЯ IgA НА ОСНОВЕ БАКТЕРИЙ LACTOBACILLUS AMYLOVORUS И ШТАММ БАКТЕРИЙ LACTOBACILLUS AMYLOVORUS CP1750 FERM BP-10532
CN100584940C (zh) * 2007-05-17 2010-01-27 江南大学 一株产精氨酸脱亚氨酶的菌种及其应用
JP5247120B2 (ja) * 2007-11-02 2013-07-24 雪印メグミルク株式会社 Ｌ−オルニチン含有物の製造方法
EE05341B1 (et) * 2008-05-13 2010-08-16 O� Tervisliku Piima Biotehnoloogiate Arenduskeskus Isoleeritud mikroorganismi tvi Lactobacillus plantarum Inducia DSM 21379 kui organismi loomulikku kaitsev?imet t?stev probiootik, seda sisaldav toiduaine ja kompositsioon ning mikroorganismi kasutamine rakulist immuunsust t?stva ravimi valmistamisek
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
CN101606952B (zh) * 2008-06-17 2012-09-19 上海交通大学医学院附属第三人民医院 乳双歧杆菌在制备预防泌尿系统结石药物中的应用
JP5526320B2 (ja) * 2008-09-04 2014-06-18 国立大学法人旭川医科大学 腸管保護剤
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CN102548565A (zh) * 2009-10-22 2012-07-04 株式会社益力多本社 癌症发病风险降低剂
US10792315B2 (en) 2010-04-08 2020-10-06 National University Corporation Asahikawa Medical University Intestinal protectant
KR101062779B1 (ko) 2010-04-28 2011-09-06 삼육대학교산학협력단 충치 유발 세균의 성장 억제 활성을 나타내는 비피도박테리움 아돌레센티스 ｓｐｍ1005 균주 및 상기 비피도박테리움 아돌레센티스 ｓｐｍ1005 균주 또는 이의 배양물을 유효 성분으로 하는 충치 예방용 식품 및 약제학 조성물
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN102433290B (zh) * 2012-01-16 2013-06-12 江南大学 一株产瓜氨酸的菌株及用该菌株生物合成瓜氨酸的方法
JP2014521602A (ja) 2012-04-04 2014-08-28 ポラリス グループ アルギニンデイミナーゼを用いる処置方法
KR102263038B1 (ko) 2013-03-15 2021-06-14 티디더블유 그룹 암치료를 위한 ａｄｉ-ｐｅｇ 20 항체에 대해 감소된 교차반응성을 지니는 아르기닌 탈이민효소
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
HK1243461A1 (zh) * 2014-01-22 2018-07-13 Meiji Co., Ltd. 瓜氨酸的制备方法
SG11201607736UA (en) 2014-03-18 2016-10-28 Tdw Group Engineered chimeric pegylated adi and methods of use
AU2015317848B2 (en) 2014-09-16 2021-04-22 Polaris Group Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for cancer treatment
MX2017008449A (es) 2014-12-23 2017-10-12 4D Pharma Res Ltd Polipeptido de pirina y modulacion inmune.
JP6271093B1 (ja) 2014-12-23 2018-01-31 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 免疫調節
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2016203218A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
PE20180242A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
EP3307288B1 (en) 2015-06-15 2019-07-24 4D Pharma Research Limited Compositions comprising bacterial strains
HRP20180501T1 (hr) 2015-11-20 2018-06-01 4D Pharma Research Limited Pripravci koje sadrže bakterijske sojeve
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN106994134B (zh) * 2016-01-25 2020-08-25 深圳华大生命科学研究院 肠道益生菌在预防和/或治疗糖尿病及其相关疾病中的应用
ME03487B (me) 2016-03-04 2020-01-20 4D Pharma Plc Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
US12281339B2 (en) 2016-07-05 2025-04-22 Polaris Group Combination cancer immunotherapies with arginine depletion agents
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
CA3039796A1 (en) 2016-11-02 2018-05-11 Polaris Group Formulations of pegylated arginine deiminase
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11179426B2 (en) * 2016-12-29 2021-11-23 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
CN108265068B (zh) * 2016-12-31 2021-06-15 江苏众红生物工程创药研究院有限公司 重组精氨酸脱亚胺酶及其产业化制备方法和应用
EP3630136B1 (en) 2017-05-22 2021-04-21 4D Pharma Research Limited Compositions comprising bacterial strains
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
DK3600363T3 (da) 2017-06-14 2021-01-25 4D Pharma Res Ltd Sammensætninger omfattende bakteriestammer
WO2018229236A2 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
MA49373B1 (fr) 2017-06-14 2021-02-26 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
RU2675110C1 (ru) * 2018-04-09 2018-12-17 Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) Фармацевтическая композиция для терапии воспалительных заболеваний слизистых оболочек кишечника на основе штамма Lactobacillus brevis 47f, проявляющая местную противовоспалительную активность
FR3082207B1 (fr) * 2018-06-06 2022-03-25 Agronomique Inst Nat Rech Nouvelle souche probiotique de lactobacillus brevis
KR102069622B1 (ko) * 2019-06-25 2020-01-23 한국식품연구원 락토바실러스 퍼멘텀 WiKim0102를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
KR20230004505A (ko) * 2020-04-17 2023-01-06 클라우디오 드 시모네 기도 질환의 치료 및 예방에서 세균 조성물의 용도
US20230293605A1 (en) * 2020-06-22 2023-09-21 Meiji Co., Ltd. Composition for promoting production of interleukin-10
KR102363111B1 (ko) * 2021-06-29 2022-02-15 (주)바이오일레븐 항염 및 항산화 활성을 갖는 락토바실러스 퍼멘텀 균주 및 이의 용도
KR102822265B1 (ko) * 2023-02-27 2025-06-19 퓨리셀매니아 주식회사 신규 락토바실러스 브리비스 균주 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415550A (en) * 1983-03-04 1983-11-15 Pakhomov Gennady N Treatment-and-prophylactic tooth paste possessing anticarious effect
JP2900279B2 (ja) * 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
US5196195A (en) 1990-03-27 1993-03-23 Cornell Research Foundation, Inc. Use of arginase to control nitric oxide formation
GB9107305D0 (en) * 1991-04-08 1991-05-22 Unilever Plc Probiotic
AUPM596894A0 (en) * 1994-05-30 1994-06-23 Hybrid Scientific Pty Ltd Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders
US5599795A (en) * 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)

Also Published As

Publication number Publication date
IN188450B (member.php) 2002-09-28
ITRM980103A0 (it) 1998-02-20
DE69839351T2 (de) 2009-06-25
HK1033338A1 (en) 2001-08-24
EP1058725A1 (en) 2000-12-13
IN1999KO00116A (member.php) 2005-03-11
EA200000856A1 (ru) 2001-02-26
JP2002504324A (ja) 2002-02-12
TR200002326T2 (tr) 2000-11-21
DE69839351D1 (de) 2008-05-21
IT1298918B1 (it) 2000-02-07
SI1058725T1 (sl) 2008-08-31
BR9815677A (pt) 2000-10-24
US7147847B2 (en) 2006-12-12
CA2321263C (en) 2009-08-11
PT1058725E (pt) 2008-06-19
CA2321263A1 (en) 1999-08-26
ES2303357T3 (es) 2008-08-01
WO1999042568A1 (en) 1999-08-26
US6572854B1 (en) 2003-06-03
KR20010106092A (ko) 2001-11-29
EP1058725B1 (en) 2008-04-09
IL137799A0 (en) 2001-10-31
CN1189560C (zh) 2005-02-16
MXPA00007990A (es) 2001-03-01
ITRM980103A1 (it) 1999-08-20
KR100594569B1 (ko) 2006-06-30
AU754483B2 (en) 2002-11-14
CN1284994A (zh) 2001-02-21
MX237377B (es) 2006-05-31
AR071841A2 (es) 2010-07-21
US20030215429A1 (en) 2003-11-20
CY1108112T1 (el) 2014-02-12
JP4253439B2 (ja) 2009-04-15
AU9644198A (en) 1999-09-06
EA006018B1 (ru) 2005-08-25
IL137799A (en) 2005-08-31
ZA9811619B (en) 1999-06-23
DK1058725T3 (da) 2008-08-18
AR020053A1 (es) 2002-04-10

Similar Documents

Publication Publication Date Title
ATE391774T1 (de) Verwendung von bakterien mit arginin- deiminaseaktivität zur induktion der apoptose und/oder zur hemmung einer entzündungsreaktion, und diese enthaltende pharmazeutische oder diätetische zusammensetzungen
DE69729646D1 (de) Formulierung zur verwendung in der vorbeugung von pathogen-induzierten erkrankungen, einschliesslich hiv und hsv
FI954729A7 (fi) Parannettuja absorbenttiosia, jotka jakauttavat nestettä parannetusti tiheydeltään ja neliömassaltaan pienten vastaanottovyöhykkeiden kautta
ATE277196T1 (de) Messung und kontrolle von sessiler und planktonischer mikrobiologischer aktivität in industriellen wassersystemen
ATE288424T1 (de) Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen
DE69927971D1 (de) Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
FI942915L (fi) Absorbenttikoostumus ja sitä sisältävä kertakäyttövaippa
DE69729284D1 (de) Filmbildende zusammensetzungen von antihyperalgesischen opiaten und deren verwendung zur behandlung von hyperalgesie
DE69535761D1 (de) System zur Steuerung der Verteilung und Benutzung von Digitalwerken
DE69535166D1 (de) System zur Steuerung der Verteilung und Benutzung von Digitalwerken
EE9900453A (et) Graanul, farmatseutiline doseerimisvorm, graanulite valmistamismeetod ja ravimiga kaetud graanulid
ITMI942025A0 (it) Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
DE69212620D1 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
DE69906671D1 (de) Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen
NO990433D0 (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
DE59905572D1 (de) Substituierte 4-amino-2-aryl-pyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
DE3667605D1 (de) Windel zur verhuetung von wundliegen.
DE69914951D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
EP0975801A4 (en) METHODS FOR SCREENING FOR ANTIMICROBIAL AGENTS USING (aarC) AND COMPOSITIONS THEREOF
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
FI951403L (fi) Polypeptidit, jotka liittyvät streptogramiinien biosynteesiin, näitä polypeptidejä koodittavat nukleotidisekvenssit, ja niiden käyttö
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
PT1017388E (pt) Composicao farmaceutica contendo ibuprofeno e domperidona para o tratamento de enxaqueca

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1058725

Country of ref document: EP